Receptors and reform: cannabinoid science and the turn of 1996–2026

For most of its long association with humans, cannabis was a plant people knew by its uses rather than its chemistry. Rope makers knew its fibre, farmers its seed, mourners its smoke, physicians its tinctures. What nobody knew, until surprisingly late in the twentieth century, was what the plant's active substances actually were, or why the human body responded to them at all. This final article in our series follows the scientific work that answered those questions, from the structure of cannabidiol in 1963 to the discovery of the body's own "cannabinoid" molecules in the early 1990s. It then traces how that science, together with the cases of particular patients, fed into thirty years of legal change between 1996 and 2026. It closes by stepping back to ask what the whole history can and cannot tell us.

A word on scope. This is history. Nothing here is advice on growing, using or obtaining cannabis, and the passages on law describe the position reported in our source material as of October 2026. They are not medical or legal advice.

Where the story stands in the 1960s

The previous article in the series, on medicine and prohibition, ended with an international control system firmly in place. The Single Convention on Narcotic Drugs of 1961 had placed cannabis and cannabis resin in its strictest categories. Official inquiries, from the Indian Hemp Drugs Commission of 1893–94 to the Wootton Report of 1968, had questioned the severity of the regime, and governments had largely set their conclusions aside.

The striking thing about this moment is how little anyone knew about the substance being regulated. Cannabis had been dropped from the US Pharmacopeia in 1942, partly because crude preparations varied unpredictably in strength (National Academies of Sciences, Engineering, and Medicine, 2017). Nobody could standardise a medicine whose active ingredient had not been identified. When the treaties were signed, the plant was controlled as a whole, without its chemistry being understood.

The late arrival of chemistry

Why cannabis resisted the chemists

Chemists had isolated the active principles of many medicinal plants long before. Morphine had been extracted from opium in the early nineteenth century, and cocaine from coca leaves by the middle of it. Many such plant drugs are alkaloids: nitrogen-containing compounds that readily form salts and crystals, which makes them comparatively easy to purify.

The active compounds of cannabis are different. They contain no nitrogen, are oily rather than crystalline, and occur in the resin as a mixture of closely related molecules that behave very similarly in the laboratory. Separating one from another, and proving which was which, was genuinely hard. As the paper on which this series is based observes, the chemical identity of the plant's active compounds was established surprisingly late.

1963: the structure of cannabidiol

The decisive work came from Raphael Mechoulam and his colleagues in Israel. In 1963 Mechoulam and Shvo published the structure of cannabidiol, now known as CBD (Mechoulam and Shvo, 1963). The title of their paper, "Hashish—I", signalled the first of a series.

What does "determining a structure" mean? A molecule is a particular arrangement of atoms joined by chemical bonds. Two substances can contain exactly the same atoms and yet behave quite differently because those atoms are arranged differently. To determine a structure is to establish that arrangement: which atom is bonded to which, where the rings and chains lie, and how the parts are oriented in space. In the 1960s chemists did this by combining several lines of evidence, from reactions that broke a molecule into recognisable pieces to measurements of how it interacted with different kinds of radiation. A structure determination is a kind of proof, assembled from many consistent observations, that a substance is this molecule and no other.

Cannabidiol is abundant in many cannabis plants, but it does not produce the intoxication associated with the drug. For decades it was regarded as something of a bystander, an "inactive cannabinoid".

1964: THC, and the matter of Δ1 versus Δ9

A year later Gaoni and Mechoulam reported the "Isolation, structure, and partial synthesis of an active constituent of hashish" (Gaoni and Mechoulam, 1964). That constituent was tetrahydrocannabinol, THC, the principal psychoactive compound of the plant. Each part of their title marks a distinct achievement:

• Isolation means obtaining the compound in pure form, separated from the related substances in the resin.
• Structure means establishing its atomic arrangement.
• Partial synthesis means making the compound in the laboratory, starting not from simple chemical building blocks but from a related natural product. Gaoni and Mechoulam confirmed their structure in part by converting CBD into THC (Mechoulam and Hanuš, 2000).

That last step was elegant. If a molecule of known structure can be turned by a well-understood reaction into the substance you have isolated, the structure you have proposed is strongly supported. It also showed how closely the two compounds are related: chemical cousins built on the same framework.

Older literature calls the compound "Δ1-THC" where modern texts say "Δ9-THC". This is not a different substance. The Greek delta and its number indicate where a particular double bond sits in the molecule, and the number depends on which system is used to count the atoms. Gaoni and Mechoulam originally designated the compound Δ1-THC; the Δ9 name, based on a different numbering convention, later became standard (Mechoulam and Hanuš, 2000).

What pure compounds made possible

The significance of 1963–64 was that researchers could now study the effects of cannabis with known, pure compounds rather than with resin or extracts of unknown strength. A pharmacologist could give a measured quantity of a single substance, and other laboratories could repeat the experiment with the same substance. The nineteenth-century problem of unpredictable potency now had a laboratory answer. The chemistry had legal consequences too: the 1971 Convention on Psychotropic Substances added international controls on tetrahydrocannabinol isomers and dronabinol (UNODC, 2020). Once the molecule had a name and a structure, it could be listed in its own right.

Yet knowing the structure of THC did not explain how it worked. For a quarter of a century after 1964, what it acted on in the body remained an open question.

A receptor in the brain

Receptors in plain terms

Most drugs act by binding to receptors. A receptor is a protein, usually sitting in the membrane that surrounds a cell, with a region shaped so that only certain molecules, called ligands, can fit and attach. When a suitable ligand binds, the receptor changes shape slightly, setting off a chain of events inside the cell. The familiar analogy is a lock and key, though real receptors are more flexible than locks.

One very large family is the G protein-coupled receptors. These proteins thread back and forth through the cell membrane. When a ligand binds on the outside, the receptor activates partner proteins on the inside, called G proteins, which relay the signal onwards. Many of the body's chemical messengers, and a large share of modern medicines, work through receptors of this family.

For years after THC was identified, some researchers suspected that cannabinoids needed no receptor at all. Being fatty molecules, they might simply dissolve into cell membranes and disturb them in a general way. Finding a specific receptor would settle the question.

What it means to "clone" a receptor

In 1990 Matsuda and her colleagues reported the "Structure of a cannabinoid receptor and functional expression of the cloned cDNA" (Matsuda et al., 1990). They had cloned a G protein-coupled receptor from rat cerebral cortex, the outer layer of the brain, that responded preferentially to psychoactive cannabinoids. It became known as CB1.

"Cloning" here has nothing to do with copying animals. Every protein is built according to instructions in a gene. To clone a receptor is to isolate the stretch of genetic material that encodes it and copy it in the laboratory. The "cDNA" in Matsuda's title is a DNA copy made from the messenger molecules a cell uses when building a protein. With that code in hand, researchers can deduce the protein's sequence, and they can insert the code into cells that do not normally make the receptor. If those cells then respond to cannabinoids, this gene evidently produces a working cannabinoid receptor. That is what "functional expression" means.

The result mattered because it showed that cannabinoids act through a specific, dedicated receptor rather than by vaguely disturbing membranes, and because the receptor's preference for the psychoactive compounds linked events in the cell to what people experience.

A second receptor: CB2

In 1993 Munro, Thomas and Abu-Shaar described a second receptor, which they characterised as "peripheral" (Munro, Thomas and Abu-Shaar, 1993). CB2 is found mainly outside the brain and has been particularly associated with the immune system. Its discovery suggested that cannabinoid signalling was not only a matter of the mind. Whatever the system was for, it reached well beyond the nervous system.

The body's own cannabinoids

Why a receptor implies a key

The discovery of CB1 posed an obvious puzzle. Bodies do not build receptors on the off chance of meeting a particular plant. A receptor in the mammalian brain must exist for a reason, most likely because the body makes its own molecule to activate it. Such a molecule is called an endogenous ligand. The opioid story offered a precedent: the discovery of opioid receptors in the 1970s was followed by the identification of the body's own opioid-like peptides, the endorphins and enkephalins.

Anandamide, 1992

In 1992 a team that included Devane, Hanuš, Pertwee and Mechoulam reported the "Isolation and structure of a brain constituent that binds to the cannabinoid receptor" (Devane et al., 1992). Working with porcine (pig) brain, they isolated a derivative of arachidonic acid, a fatty acid, which bound to the cannabinoid receptor. They named it "anandamide", from the Sanskrit ānanda, "bliss". Readers of the earlier articles will recall that Sanskrit was also the language of the Atharvaveda and of the South Asian traditions of bhang and ganja.

2-AG and the endocannabinoid system

A second endogenous ligand, 2-arachidonoylglycerol (2-AG), is also a lipid, or fat-derived, molecule. Together, the receptors, their endogenous ligands and the machinery that makes and breaks down those ligands came to be called the endocannabinoid system: a lipid signalling network involved in neural, immune and metabolic regulation.

The name needs careful reading. "Endocannabinoid" means "a cannabinoid from within". The system was named after the plant because the plant led scientists to it, not because it exists to respond to cannabis. The plant's compounds happen to fit receptors that animals were already using for their own purposes.

A change of frame

These discoveries changed how cannabis was understood scientifically: from an exotic intoxicant to a key to an endogenous physiological system. That shift mattered outside the laboratory. A drug understood as acting on a normal regulatory system invites different questions, and different policies, from one understood only as a source of intoxication.

It is important not to overstate what was established. Identifying a signalling system does not show that any particular cannabis product is a safe or effective treatment for any condition. That requires a different kind of evidence.

From "inactive cannabinoid" to licensed medicine

Dravet syndrome and how a trial works

Because it does not produce the psychoactive effects of THC, CBD had long been treated as the less interesting compound. Over time, interest grew in whether it might nonetheless have medical uses, epilepsy among them, and eventually the question was put to the most rigorous test medicine has.

Dravet syndrome is a rare and severe form of epilepsy that begins in early childhood, and its seizures often respond poorly to existing medicines; the trial discussed here concerned "drug-resistant seizures" (Devinsky et al., 2017). It was a randomised placebo-controlled trial, and its logic is worth spelling out:

• Randomised. Participants are assigned to treatment or comparison by chance, not by choice, so the groups should on average be alike in every respect except the treatment, including in ways nobody thought to measure.
• Placebo-controlled. The comparison group receives a preparation that looks and is given like the real one but lacks the active substance. Seizure frequency can rise and fall for many reasons, and simply being in a trial can change what is observed. The placebo group shows how much change would have happened anyway.
• Blinding. In well-run trials of this kind, neither the families nor the clinicians assessing outcomes know who received which preparation, so that expectations cannot colour the results.

Reading the Dravet figures

The result was reported as changes in the median frequency of convulsive seizures per month. On cannabidiol, the median fell from 12.4 to 5.9. On placebo, it went from 14.9 to 14.1 (Devinsky et al., 2017).

A median is the middle value when everyone's figures are lined up in order, and it is often preferred to an average in studies like this because a few extreme counts could otherwise distort the picture. Read side by side, the numbers are clear. In the cannabidiol group the median monthly count fell by more than half; in the placebo group it barely moved. The placebo group does exactly its job, showing that the fall in the treated group was not simply the ordinary drift of a fluctuating condition.

Two cautions keep the result in proportion. A median describes the middle of a group, not every child's experience. And the trial tested a purified preparation of one compound in one rare condition; it says nothing directly about other products, compounds or illnesses.

Epidiolex, 25 June 2018

On 25 June 2018 the US Food and Drug Administration approved Epidiolex, a cannabidiol oral solution, for seizures associated with Lennox–Gastaut syndrome and Dravet syndrome, two rare and severe epilepsies. The FDA described it as the first FDA-approved drug containing a purified substance derived from marijuana (US Food and Drug Administration, 2018).

The wording matters. What was approved was not "cannabis" but a purified, standardised compound tested in controlled trials, like any other new medicine. Epidiolex represents the full arc of the scientific story: the chemistry of 1963 identified the molecule, modern pharmacology made it possible to produce and measure it precisely, and the randomised trial supplied evidence of the kind regulators require.

How drug scheduling works

Almost every modern drug law sorts substances into categories, called schedules or classes, according to judgements about harm and medical value. "Rescheduling" a substance can change who may prescribe it, how it must be handled and what penalties apply, without repealing the law itself.

Two features shape what follows. The systems are nested: the UN conventions bind the states party to them, so a country that departs from the treaty framework accepts tension with its international obligations. And the systems are built around a medical distinction, between substances with recognised medical value and those without. That is why medical evidence became the most effective lever for change.

Reform, 1996–2026

California, 1996: reform from below

Reform began not at the level of nations but of a single American state. In 1996 California voters approved Proposition 215, which created the first state medical cannabis programme (National Academies of Sciences, Engineering, and Medicine, 2017). A "proposition" is a measure placed directly before voters, so this change came from the electorate rather than from legislators. Many other states followed, first with medical and then with adult-use regimes, all in conflict with federal law, under which cannabis remained in Schedule I. For three decades the United States lived with that contradiction.

Uruguay, 2013: the first national legal market

Uruguay became the first country to create a fully state-regulated legal market. Law No. 19.172, Regulación y control del cannabis ("Regulation and control of cannabis"), was passed by the Senate on 10 December 2013 and promulgated on 20 December 2013 (Uruguay, 2013). Promulgation is the formal act by which the executive proclaims a law the legislature has passed, giving it official force and ordering its publication. The two dates mark the difference between a bill that has completed its passage and a law the state has formally adopted.

Canada, 2018: the first G7 country

Canada's Cannabis Act received Royal Assent on 21 June 2018 and came into force on 17 October 2018, making Canada the first G7 country to legalise adult use nationally (Canada, 2018). In Westminster-style parliamentary systems, a bill passed by Parliament becomes law only when it receives Royal Assent, the formal approval given on behalf of the Crown; in Canada it is granted by the Governor General or a deputy. Royal Assent makes a bill an Act, but many Acts specify a later date on which they come into force, leaving time to build regulations and licensing systems. The G7 groups seven large industrialised democracies: Canada, France, Germany, Italy, Japan, the United Kingdom and the United States. Canada's move mattered because it was a major economy and a close ally of the states that had built the international control system.

Germany, 2024: a non-commercial model

Germany's Cannabis Act (CanG) came into force on 1 April 2024. It permits adults to possess limited quantities, to grow a small number of plants at home and to join non-profit cultivation associations, but it does not create a commercial retail market ("Germany's cannabis act", 2024). That last point is easily missed. Germany did not follow the Canadian or Uruguayan route of a licensed supply chain selling to the public; its model rests on personal and collective non-commercial supply. Whether that model is an endpoint or a stage, and whether it will act as what one commentary called "a catalyst for European drug policy reform", remains an open question.

The United Kingdom, 2018: a reform driven by two children

The following describes the legal position as reported in the source paper. It is historical description, not legal or medical advice.

In the United Kingdom, change came through the cases of two children with severe epilepsy, Alfie Dingley and Billy Caldwell. In June 2018 Billy Caldwell's cannabis oil was confiscated at Heathrow Airport. He was subsequently hospitalised, and the Home Secretary granted an emergency licence (House of Commons Health and Social Care Committee, 2019). The episode crystallised a contradiction: a substance in Schedule 1, the category for substances regarded as having no recognised medicinal use, was being sought for a child with a life-threatening condition.

Reviews by the Chief Medical Officer and the Advisory Council on the Misuse of Drugs followed. As a result, "cannabis-based products for medicinal use in humans" were moved from Schedule 1 to Schedule 2 of the Misuse of Drugs Regulations 2001 with effect from 1 November 2018, allowing specialist doctors to prescribe them (Home Office, 2018).

The reform was real but narrow. A parliamentary committee later noted that very few NHS prescriptions had been issued; NHS Business Services Authority data cited by the Royal College of Psychiatrists showed "fewer than 10 NHS prescriptions for CBPMs issued in primary care since November 2018" as of March 2019 (House of Commons Health and Social Care Committee, 2019; Royal College of Psychiatrists, 2019). CBPMs are cannabis-based products for medicinal use.

Just as important is what the change did not do. Cultivation and possession of cannabis outside this framework remain criminal offences in the UK, and a patient's prescription does not authorise growing the plant, which still requires a Home Office licence (Home Office, 2018). For readers of a site about indoor cultivation, this deserves emphasis: rescheduling altered what specialist doctors may prescribe, not the law on growing cannabis, for patients or anyone else.

The United Nations, 2020: a symbolic vote

In January 2019, following a critical review by its Expert Committee on Drug Dependence, the World Health Organization sent eight recommendations on cannabis and cannabis-related substances to the UN Commission on Narcotic Drugs (CND), the body of member states that decides on international scheduling. On 2 December 2020 the Commission voted by 27 to 25, with one abstention, to delete cannabis and cannabis resin from Schedule IV of the 1961 Convention (UNODC, 2020). The narrow margin is telling: nearly sixty years after the treaty, the states on the Commission were almost evenly divided.

Because Schedule IV is an extra layer on top of Schedule I, removal did not end international control. Cannabis and cannabis resin remain in Schedule I (UNODC, 2020; United Nations, 1961). The decision was symbolically significant, because it acknowledged the therapeutic value that Schedule IV had denied since 1961, but its legal effect was modest, and the Commission rejected the WHO's other recommendations.

The United States, 2026: rescheduling in part

Following an executive order in December 2025, a final order published on 28 April 2026 placed FDA-approved products containing marijuana, and marijuana subject to a state medical marijuana licence, in Schedule III of the Controlled Substances Act (Drug Enforcement Administration, 2026; Congressional Research Service, 2026). Schedule III covers substances with accepted medical use and lower abuse potential than Schedules I and II, so this is a formal federal acknowledgement of medical use, three decades after California's voters made the same judgement for their state.

The limits matter as much as the change. Non-medical ("adult-use") marijuana remains in Schedule I. Proceedings on rescheduling all marijuana opened on 29 June 2026 and, as of October 2026, were under a stay, a formal pause, ordered by the DEA's chief administrative law judge. Their outcome is uncertain and should not be anticipated.

A reform timeline

Why the reforms were framed medically

One feature stands out across these episodes: the arguments that moved legislators, regulators and international bodies were mostly medical. California began with a medical programme. The UK changed its law because of children with epilepsy. The UN vote turned on therapeutic value. The US order of 2026 rescheduled medical categories and left adult use where it was.

There are structural reasons for this. As the scheduling table shows, the control systems draw their sharpest line between substances with and without accepted medical value, so medical evidence is the lever the systems themselves provide. Cannabinoid science supplied that evidence: purified compounds, identified receptors, an endogenous signalling system and, in at least one case, a trial strong enough to satisfy a drug regulator. As the source paper puts it in summary, the reforms of 1996–2026 were justified mainly in medical terms, drawing on cannabinoid pharmacology (Devane et al., 1992; Devinsky et al., 2017). There is a human reason too. Abstract policy debates stall easily; the image of a sick child's medicine confiscated at an airport does not.

Closing reflections: what the long history suggests

The source paper ends with a discussion of what the whole arc, from Neolithic seeds to the orders of 2026, means. Its reflections apply to the entire series.

Cannabis as a companion species

Cannabis is best understood as a "companion species", a plant whose evolutionary path has been shaped by human selection for different products. Genomic data show divergence between hemp-type and drug-type lineages after domestication (Ren et al., 2021). Archaeology shows seeds and fibre long before securely attested psychoactive use (Long et al., 2017). The elevated THC signals at Jirzankal suggest that, by the first millennium BCE, some communities were selecting or seeking out chemically potent plants (Ren et al., 2019). The plant's history resembles that of other multi-purpose crops more than the image of a single "drug plant" suggests.

Shifting moral and legal framings

The moral framing of cannabis has shifted repeatedly. Medieval Islamic jurists debated hashish in terms of intoxication and public order (Rosenthal, 1971). Colonial British officials first taxed hemp drugs, then commissioned an inquiry that found moderate use largely harmless, then took part in international control for reasons rooted in imperial diplomacy (Indian Hemp Drugs Commission, 1894; Mills, 2003). Twentieth-century prohibition was consolidated despite official inquiries recommending more lenient approaches (Advisory Committee on Drug Dependence, 1968; National Commission on Marihuana and Drug Abuse, 1972). And the recent reforms rested on medicine.

The evidence suggests that legal status has tracked politics, empire and medical paradigms more than changes in the plant's pharmacology, which has remained broadly constant. What changed, again and again, was not the plant but the frameworks through which people looked at it.

Four historiographical traps

Readers of this series will have met all four problems the source paper identifies:

• Overclaiming. Advocacy literature often presents contested identifications (Egyptian papyri, Hua Tuo's anaesthetic, Assyrian plant names) or unverified anecdotes (hemp-paper documents) as fact.
• Presentism. Ancient ritual fumigation is read as "recreational use", or ancient medical uses as validation of modern products.
• Legend and Orientalism. The "Assassins" story shows how European fantasies about the East were built into drug history (Daftary, 1994).
• Polarisation. Both prohibitionist and pro-legalisation literatures have selected evidence to suit policy goals.

The corrective is careful recent scholarship of the kind this series has drawn on: residue chemistry, critical pollen synthesis and archival history of empire (Arie, Rosen and Namdar, 2020; McPartland, Hegman and Long, 2019; Mills, 2003; Duvall, 2019). These approaches share a habit of asking what a piece of evidence can actually support.

Gaps in the evidence

Significant gaps remain. The chronology between initial domestication and the first residue evidence spans millennia with little direct chemical evidence. Africa's pre-colonial cannabis history depends heavily on linguistic and ethnographic inference. The genomic picture is complicated by modern hybridisation and by sampling biased towards China and commercial cultivars. The most promising directions are further residue studies on securely dated vessels, ancient DNA from archaeobotanical remains, and archival work on non-European regulatory histories. The source paper is also candid about its own limits: it is a narrative rather than a systematic review, and non-English scholarship, particularly in Chinese, Japanese and Russian, is under-represented in it.

What we know, and what we don't

What we know with reasonable confidence:

• The structures of CBD (1963) and THC (1964) were established by Mechoulam and colleagues, and THC's structure was confirmed in part by converting CBD into it.
• Cannabinoids act through specific G protein-coupled receptors: CB1, cloned in 1990, and the mainly peripheral CB2, cloned in 1993.
• The body makes its own cannabinoid ligands, including anandamide and 2-AG, part of a signalling network involved in neural, immune and metabolic regulation.
• In a randomised placebo-controlled trial in Dravet syndrome, purified cannabidiol was associated with a far larger fall in median monthly convulsive seizures than placebo, and the FDA approved a CBD medicine in 2018.
• Cannabis remains in Schedule I of the 1961 Convention, though no longer in Schedule IV.
• In the UK, specialist doctors have been able to prescribe cannabis-based products for medicinal use since 1 November 2018, but growing the plant still requires a Home Office licence.

What we don't know, or can't yet say:

• The outcome of the US proceedings on rescheduling all marijuana, paused as of October 2026.
• Whether Germany's non-commercial model will prove stable or influential elsewhere.
• How to fill the long gap between domestication and the first secure evidence of psychoactive use.
• How much of Africa's pre-colonial cannabis history can be recovered beyond linguistic and ethnographic inference.
• What evidence for one purified compound in one rare condition implies for other compounds, products or conditions. On its own, very little.

The lesson of the inquiries

The source paper's final lesson is addressed to policymakers: official inquiries, from 1894 onward, repeatedly reached more nuanced conclusions than the laws that followed them. The Indian Hemp Drugs Commission concluded that moderate use was "practically attended by no evil results at all", while accepting that excessive use could be "very injurious", and recommended regulation and taxation rather than prohibition (Indian Hemp Drugs Commission, 1894). Three decades later, cannabis entered international law at Geneva largely for imperial and diplomatic reasons (Mills, 2003). The Wootton, Shafer and Le Dain reports argued for more measured approaches around 1970 (Advisory Committee on Drug Dependence, 1968; National Commission on Marihuana and Drug Abuse, 1972; Commission of Inquiry into the Non-Medical Use of Drugs, 1972). Each was largely set aside by the governments that had commissioned it, much as the Indian report had been.

None of this tells us what the right policy is; inquiries can be wrong, and nuance is not a policy. But the recurring gap between careful investigation and the law that followed is itself a historical fact, and a useful one.

The series in brief

This series has followed one plant through more than ten thousand years of human company:

1. Origins set out the botany: a genus that probably arose on the north-eastern Tibetan Plateau, a disputed taxonomy, and genomic evidence for an early-Neolithic domestication in East Asia.
2. Prehistory followed fibre and seed across Eurasia, from Jōmon Japan to the steppe, and the difference between pollen, macrofossil and residue evidence.
3. Antiquity examined the first chemical evidence of psychoactive use, at Yanghai, Jirzankal and Tel Arad, alongside claims about Egypt and China that need caution.
4. The medieval world and trade traced hashish in Islamic societies, the "Assassins" legend, the plant's African roots and Atlantic crossing, and hemp as a strategic crop.
5. Medicine and prohibition followed cannabis into and out of Western medicine and through the building of international control.
6. Receptors and reform, this article, has traced the science that reframed the plant and the partial legal reversal of 1996–2026.

Across all six, one theme recurs. Cannabis has been rope, food, medicine, sacrament, commodity, vice and pharmaceutical, often at the same time in different places. Its pharmacology has stayed broadly constant while the human frameworks around it have changed repeatedly. Prohibition was a recent and politically contingent episode in a much longer history, now being partially reversed under the influence of cannabinoid science and medical need. The historian's task is to separate evidence from legend, and to place cannabis within the wider histories of agriculture, empire and medicine.

Sources

Advisory Committee on Drug Dependence (1968) Cannabis (the Wootton Report). London: HMSO.

Arie, E., Rosen, B. and Namdar, D. (2020) 'Cannabis and frankincense at the Judahite shrine of Arad', Tel Aviv, 47(1), pp. 5–28. doi:10.1080/03344355.2020.1732046.

Canada (2018) Cannabis Act (S.C. 2018, c. 16). Royal Assent 21 June 2018; in force 17 October 2018. Ottawa: Government of Canada.

Commission of Inquiry into the Non-Medical Use of Drugs (1972) Cannabis (the Le Dain Commission report). Ottawa: Information Canada.

Congressional Research Service (2026) Department of Justice Eases Control of Medical Marijuana (Legal Sidebar LSB11424). Washington, DC: Library of Congress. Available at: https://www.congress.gov/crs-product/LSB11424.

Daftary, F. (1994) The Assassin Legends: Myths of the Isma'ilis. London: I.B. Tauris.

Devane, W.A., Hanuš, L., Breuer, A., Pertwee, R.G., Stevenson, L.A., Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A. and Mechoulam, R. (1992) 'Isolation and structure of a brain constituent that binds to the cannabinoid receptor', Science, 258(5090), pp. 1946–1949. doi:10.1126/science.1470919.

Devinsky, O., Cross, J.H., Laux, L., Marsh, E., Miller, I., Nabbout, R., Scheffer, I.E., Thiele, E.A. and Wright, S. (2017) 'Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome', New England Journal of Medicine, 376(21), pp. 2011–2020. doi:10.1056/NEJMoa1611618.

Drug Enforcement Administration (2026) 'Schedules of Controlled Substances: Rescheduling of Food and Drug Administration approved products containing marijuana from Schedule I to Schedule III; corresponding change to permit requirements', Federal Register, 91 FR 22714, 28 April 2026 (Document 2026-08176).

Duvall, C.S. (2019) The African Roots of Marijuana. Durham, NC: Duke University Press. doi:10.2307/j.ctv11hpqx7.

Gaoni, Y. and Mechoulam, R. (1964) 'Isolation, structure, and partial synthesis of an active constituent of hashish', Journal of the American Chemical Society, 86(8), pp. 1646–1647. doi:10.1021/ja01062a046.

'Germany's cannabis act: a catalyst for European drug policy reform?' (2024) The Lancet Regional Health – Europe. Available at: https://www.thelancet.com/journals/lanepe/article/PIIS2666-7762(24)00096-6/fulltext.

Home Office (2018) Home Office Circular 2018: Rescheduling of cannabis-based products for medicinal use in humans. Issued 1 November 2018. London: Home Office.

House of Commons Health and Social Care Committee (2019) Drugs policy: medicinal cannabis (HC 1821). London: House of Commons.

Indian Hemp Drugs Commission (1894) Report of the Indian Hemp Drugs Commission, 1893–94. Simla: Government Central Printing Office.

Long, T., Wagner, M., Demske, D., Leipe, C. and Tarasov, P.E. (2017) 'Cannabis in Eurasia: origin of human use and Bronze Age trans-continental connections', Vegetation History and Archaeobotany, 26, pp. 245–258. doi:10.1007/s00334-016-0579-6.

Matsuda, L.A., Lolait, S.J., Brownstein, M.J., Young, A.C. and Bonner, T.I. (1990) 'Structure of a cannabinoid receptor and functional expression of the cloned cDNA', Nature, 346, pp. 561–564. doi:10.1038/346561a0.

McPartland, J.M., Hegman, W. and Long, T. (2019) 'Cannabis in Asia: its center of origin and early cultivation, based on a synthesis of subfossil pollen and archaeobotanical studies', Vegetation History and Archaeobotany, 28(6), pp. 691–702. doi:10.1007/s00334-019-00731-8.

Mechoulam, R. and Hanuš, L. (2000) 'A historical overview of chemical research on cannabinoids', Chemistry and Physics of Lipids, 108, pp. 1–13.

Mechoulam, R. and Shvo, Y. (1963) 'Hashish—I: The structure of cannabidiol', Tetrahedron, 19, pp. 2073–2078.

Mills, J.H. (2003) Cannabis Britannica: Empire, Trade, and Prohibition 1800–1928. Oxford: Oxford University Press.

Munro, S., Thomas, K.L. and Abu-Shaar, M. (1993) 'Molecular characterization of a peripheral receptor for cannabinoids', Nature, 365, pp. 61–65.

National Academies of Sciences, Engineering, and Medicine (2017) The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. Washington, DC: The National Academies Press. Available at: https://www.ncbi.nlm.nih.gov/books/NBK425762/.

National Commission on Marihuana and Drug Abuse (1972) Marihuana: A Signal of Misunderstanding. Washington, DC: US Government Printing Office.

Ren, G., Zhang, X., Li, Y., Ridout, K., Serrano-Serrano, M.L., Yang, Y., Liu, A., Ravikanth, G., Nawaz, M.A., Mumtaz, A.S., Salamin, N. and Fumagalli, L. (2021) 'Large-scale whole-genome resequencing unravels the domestication history of Cannabis sativa', Science Advances, 7(29), eabg2286. doi:10.1126/sciadv.abg2286.

Ren, M., Tang, Z., Wu, X., Spengler, R., Jiang, H., Yang, Y. and Boivin, N. (2019) 'The origins of cannabis smoking: chemical residue evidence from the first millennium BCE in the Pamirs', Science Advances, 5(6), eaaw1391. doi:10.1126/sciadv.aaw1391.

Rosenthal, F. (1971) The Herb: Hashish versus Medieval Muslim Society. Leiden: E.J. Brill.

Royal College of Psychiatrists (2019) Position statement on the use of medicinal cannabis (PS05/19). London: Royal College of Psychiatrists.

United Nations (1961) Single Convention on Narcotic Drugs, 1961. New York, 30 March 1961; entered into force 13 December 1964. United Nations Treaty Series, vol. 520.

UNODC (2020) CND votes on recommendations for cannabis and cannabis-related substances. Vienna, 3 December 2020. Available at: https://www.unodc.org/unodc/en/frontpage/2020/December/cnd-votes-on-recommendations-for-cannabis-and-cannabis-related-substances.html.

Uruguay (2013) Ley N° 19.172: Regulación y control del cannabis. Montevideo: República Oriental del Uruguay (promulgated 20 December 2013).

US Food and Drug Administration (2018) FDA approves first drug comprised of an active ingredient derived from marijuana to treat rare, severe forms of epilepsy (press release, 25 June 2018). Silver Spring, MD: FDA.